{"id":742130,"date":"2011-04-11T07:01:00","date_gmt":"2011-04-11T07:01:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-co-inc-and-sun-pharma-establish-joint-venture-to-develop-and-commercialize-novel-formulations-and-combinations-of-medicines-in-emerging-markets\/"},"modified":"2026-08-10T13:01:18","modified_gmt":"2026-08-10T17:01:18","slug":"merck-co-inc-and-sun-pharma-establish-joint-venture-to-develop-and-commercialize-novel-formulations-and-combinations-of-medicines-in-emerging-markets","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-co-inc-and-sun-pharma-establish-joint-venture-to-develop-and-commercialize-novel-formulations-and-combinations-of-medicines-in-emerging-markets\/","title":{"rendered":"Merck &amp; Co., Inc., and Sun Pharma Establish Joint Venture to Develop and Commercialize Novel Formulations and Combinations of Medicines in Emerging Markets"},"content":{"rendered":"<p class=\"bwalignc\">       Joint Venture to Apply Proprietary Technologies to Develop Medicines        Designed to Enhance Convenience and Improve Compliance     <\/p>\n<p>Merck &amp; Co., Inc., (NYSE:MRK), a global health care leader, known as MSD<br \/>\n      outside the United States and Canada, and Sun Pharmaceutical Industries<br \/>\n      Ltd., (\u201cSun Pharma\u201d) a leading Indian multinational pharmaceutical<br \/>\n      company, today announced the creation of a joint venture to develop,<br \/>\n      manufacture and commercialize new combinations and formulations of<br \/>\n      innovative, branded generics in the Emerging Markets.\n    <\/p>\n<p>\n      &#8220;Merck&#8217;s Emerging Markets strategy is driven by our overarching focus on<br \/>\n      applying innovation across our business from introducing novel compounds<br \/>\n      to broadening our focus on innovative branded generics,&#8221; said Kevin Ali,<br \/>\n      president, Emerging Markets, Merck\/MSD. &#8220;By combining forces with Sun<br \/>\n      Pharma, we are complementing our innovative product portfolio with a<br \/>\n      solid foundation for addressing the diverse needs of patients,<br \/>\n      physicians and governments across the Emerging Markets.&#8221;\n    <\/p>\n<p>\n      The partnership combines Sun Pharma&#8217;s proven track record of leadership<br \/>\n      and expertise in rapid, innovative product development using Sun Pharma<br \/>\n      Advanced Research Company Ltd&#8217;s (&#8220;SPARC&#8221;) proprietary platform<br \/>\n      technologies, and Sun Pharma\u2019s world-class manufacturing network with<br \/>\n      Merck&#8217;s clinical development and registration expertise and a broad,<br \/>\n      geographic commercial footprint. The companies said that they will focus<br \/>\n      on &#8216;innovative branded generics,&#8217; that bring together combinations of<br \/>\n      medicines using platform delivery technologies designed to enhance<br \/>\n      convenience for patients in Emerging Markets. The joint venture will be<br \/>\n      structured through Merck and Sun Pharma&#8217;s respective subsidiaries.<br \/>\n      Financial details of the joint venture were not disclosed.\n    <\/p>\n<p>\n      \u201cThis joint venture reinforces our strategy of partnering to launch<br \/>\n      products using our highly innovative delivery technologies around the<br \/>\n      world,&#8221; said Dilip S. Shanghvi, chairman and managing director, Sun<br \/>\n      Pharmaceutical Industries Ltd. &#8220;Merck has an unrivalled reputation as a<br \/>\n      world leading, innovative, research-driven pharmaceutical company. We\u2019re<br \/>\n      proud to be associated with them and look forward to working together.&#8221;\n    <\/p>\n<p>\n      Experts estimate that during the coming decade, the Emerging Markets are<br \/>\n      expected to drive 90 percent of the world&#8217;s pharmaceutical growth, with<br \/>\n      75 percent of that growth coming from branded generics. In these<br \/>\n      markets, the growing burden of chronic disease, such as cardiovascular<br \/>\n      disease, diabetes and hepatitis, along with an increasing population and<br \/>\n      economic prosperity, is leading to an increased demand for branded<br \/>\n      generics.\n    <\/p>\n<p>\n      &#8220;Merck has a proud legacy of developing innovative medicines and<br \/>\n      vaccines with proven ability to impact global human health,&#8221; said Ali.<br \/>\n      &#8220;We are making good progress executing on our Emerging Markets growth<br \/>\n      strategy by establishing novel partnerships and strategic alliances.<br \/>\n      This joint venture helps position us for leadership in the fastest<br \/>\n      growing geographies.&#8221;\n    <\/p>\n<p>\n      The collaboration between MSD and Sun Pharma will be managed by a Joint<br \/>\n      Board and leadership team, consisting of members of senior management<br \/>\n      from both companies.\n    <\/p>\n<p>\n      <b>About Sun Pharmaceutical Industries Ltd.<\/b>\n    <\/p>\n<p>\n      Established in 1983, listed since 1994 and headquartered in India, Sun<br \/>\n      Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN,<br \/>\n      NSE: SUNPHARMA, BSE: 524715) is an international, integrated, specialty<br \/>\n      pharmaceutical company. The company manufactures and markets a large<br \/>\n      number of pharmaceutical formulations as branded and incrementally<br \/>\n      innovative generics in India, the United States and across several<br \/>\n      Emerging Markets. In India, it is the leader across the psychiatry,<br \/>\n      neurology, cardiology, diabetology, gastroenterology, ophthalmology and<br \/>\n      orthopedic therapy areas. Additionally, the company possesses strong<br \/>\n      skills in product development, process chemistry, and the manufacturing<br \/>\n      of complex active pharmaceutical ingredients (APIs) as well as dosage<br \/>\n      formulations. More information can be found at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sunpharma.com&amp;esheet=50284411&amp;lan=en-US&amp;anchor=www.sunpharma.com&amp;index=1&amp;md5=78ede97acd70199375f5d7996a4092da\">www.sunpharma.com<\/a>.\n    <\/p>\n<p>\n      <b>About Sun Pharma Advanced Research Company Ltd<\/b>\n    <\/p>\n<p>\n      SPARC Ltd. is a listed, independent R&amp;D company that discovers and<br \/>\n      develops new molecules and novel drug delivery systems, with a<br \/>\n      220+-strong team of scientists and four R&amp;D centers.\n    <\/p>\n<p>\n      SPARC\u2019s delivery system projects focus on developing platform<br \/>\n      technologies that enhance patient convenience or compliance, such as<br \/>\n      oral (gastro retentive innovative device, wrap matrix technology),<br \/>\n      injectables (nanoparticulate formulations, biodegradable depots), dry<br \/>\n      powder inhalers, ophthalmic technologies (swollen micelle and gel free<br \/>\n      reservoir). Some products based on these technologies are marketed in<br \/>\n      India.\n    <\/p>\n<p>\n      <b>About Merck &amp; Co., Inc.<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com&amp;esheet=50284411&amp;lan=en-US&amp;anchor=www.merck.com&amp;index=2&amp;md5=a68a8da2666fb7b00260be48219e9b12\">www.merck.com<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. Such statements may include,<br \/>\n      but are not limited to, statements about the benefits of the merger<br \/>\n      between Merck and Schering-Plough, including future financial and<br \/>\n      operating results, the combined company\u2019s plans, objectives,<br \/>\n      expectations and intentions and other statements that are not historical<br \/>\n      facts. Such statements are based upon the current beliefs and<br \/>\n      expectations of Merck\u2019s management and are subject to significant risks<br \/>\n      and uncertainties. Actual results may differ from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      The following factors, among others, could cause actual results to<br \/>\n      differ from those set forth in the forward-looking statements: the<br \/>\n      possibility that the expected synergies from the merger of Merck and<br \/>\n      Schering-Plough will not be realized, or will not be realized within the<br \/>\n      expected time period; the impact of pharmaceutical industry regulation<br \/>\n      and healthcare legislation; the risk that the businesses will not be<br \/>\n      integrated successfully; disruption from the merger making it more<br \/>\n      difficult to maintain business and operational relationships; Merck\u2019s<br \/>\n      ability to accurately predict future market conditions; dependence on<br \/>\n      the effectiveness of Merck\u2019s patents and other protections for<br \/>\n      innovative products; the risk of new and changing regulation and health<br \/>\n      policies in the United States and internationally and the exposure to<br \/>\n      litigation and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2010 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=50284411&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=3&amp;md5=a6be3a6887feb79efcdc9a60da4f9591\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      Photos\/Multimedia&nbsp;Gallery Available: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.businesswire.com%2Fcgi-bin%2Fmmg.cgi%3Feid%3D6678689%26lang%3Den&amp;esheet=50284411&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.businesswire.com%2Fcgi-bin%2Fmmg.cgi%3Feid%3D6678689%26lang%3Den&amp;index=4&amp;md5=62759f5ccf8d0b9ead54612c8be696b2\">http:\/\/www.businesswire.com\/cgi-bin\/mmg.cgi?eid=6678689&amp;lang=en<\/a>\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120521005627r1&amp;sid=sfsite1&amp;distro=nx\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck &amp; Co., Inc.<br \/>Media:<br \/>Ian R. McConnell,        908-423-3046<br \/>or Gail S. Thornton, 908-423-3012<br \/>or Jyotsna        Ghoshal, +91 98 1019 4171<br \/>or<br \/>Investors:<br \/>Joe Romanelli,        908-423-5088<br \/>or Carol Ferguson, 908-423-4465<br \/>or<br \/>Sun        Pharmaceutical Industries Ltd.<br \/>Media and Investors:<br \/>Uday        Baldota, + 91 98 6701 0529<br \/>or Mira Desai, + 91 98219 23797     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Joint Venture to Apply Proprietary Technologies to Develop Medicines Designed to Enhance Convenience and Improve Compliance Merck &amp; Co., Inc., (NYSE:MRK), a global health care leader, known as MSD outside the United States and Canada, and Sun Pharmaceutical Industries Ltd., (\u201cSun Pharma\u201d) a leading Indian multinational pharmaceutical company, today announced the creation of a joint venture to develop, manufacture and commercialize new combinations and formulations of innovative, branded generics in the Emerging Markets. &#8220;Merck&#8217;s Emerging Markets strategy is driven by our overarching focus on applying innovation across our business from introducing novel compounds to broadening our focus on innovative branded generics,&#8221; said Kevin Ali, president, Emerging Markets, Merck\/MSD. &#8220;By combining forces with Sun Pharma, we are complementing our innovative product portfolio with a solid foundation for addressing the diverse needs of patients, physicians and governments across the Emerging<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289],"class_list":["post-742130","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck &amp; Co., Inc., and Sun Pharma Establish Joint Venture to Develop and Commercialize Novel Formulations and Combinations of Medicines in Emerging Markets - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-co-inc-and-sun-pharma-establish-joint-venture-to-develop-and-commercialize-novel-formulations-and-combinations-of-medicines-in-emerging-markets\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck &amp; Co., Inc., and Sun Pharma Establish Joint Venture to Develop and Commercialize Novel Formulations and Combinations of Medicines in Emerging Markets - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Joint Venture to Apply Proprietary Technologies to Develop Medicines Designed to Enhance Convenience and Improve Compliance Merck &amp; Co., Inc., (NYSE:MRK), a global health care leader, known as MSD outside the United States and Canada, and Sun Pharmaceutical Industries Ltd., (\u201cSun Pharma\u201d) a leading Indian multinational pharmaceutical company, today announced the creation of a joint venture to develop, manufacture and commercialize new combinations and formulations of innovative, branded generics in the Emerging Markets. &quot;Merck&#039;s Emerging Markets strategy is driven by our overarching focus on applying innovation across our business from introducing novel compounds to broadening our focus on innovative branded generics,&quot; said Kevin Ali, president, Emerging Markets, Merck\/MSD. &quot;By combining forces with Sun Pharma, we are complementing our innovative product portfolio with a solid foundation for addressing the diverse needs of patients, physicians and governments across the Emerging\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-co-inc-and-sun-pharma-establish-joint-venture-to-develop-and-commercialize-novel-formulations-and-combinations-of-medicines-in-emerging-markets\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T17:01:18+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120521005627r1&amp;sid=sfsite1&amp;distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-co-inc-and-sun-pharma-establish-joint-venture-to-develop-and-commercialize-novel-formulations-and-combinations-of-medicines-in-emerging-markets\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-co-inc-and-sun-pharma-establish-joint-venture-to-develop-and-commercialize-novel-formulations-and-combinations-of-medicines-in-emerging-markets\\\/\",\"name\":\"Merck &amp; Co., Inc., and Sun Pharma Establish Joint Venture to Develop and Commercialize Novel Formulations and Combinations of Medicines in Emerging Markets - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-co-inc-and-sun-pharma-establish-joint-venture-to-develop-and-commercialize-novel-formulations-and-combinations-of-medicines-in-emerging-markets\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-co-inc-and-sun-pharma-establish-joint-venture-to-develop-and-commercialize-novel-formulations-and-combinations-of-medicines-in-emerging-markets\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120521005627r1&amp;sid=sfsite1&amp;distro=nx\",\"datePublished\":\"2011-04-11T07:01:00+00:00\",\"dateModified\":\"2026-08-10T17:01:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-co-inc-and-sun-pharma-establish-joint-venture-to-develop-and-commercialize-novel-formulations-and-combinations-of-medicines-in-emerging-markets\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-co-inc-and-sun-pharma-establish-joint-venture-to-develop-and-commercialize-novel-formulations-and-combinations-of-medicines-in-emerging-markets\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-co-inc-and-sun-pharma-establish-joint-venture-to-develop-and-commercialize-novel-formulations-and-combinations-of-medicines-in-emerging-markets\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120521005627r1&amp;sid=sfsite1&amp;distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120521005627r1&amp;sid=sfsite1&amp;distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-co-inc-and-sun-pharma-establish-joint-venture-to-develop-and-commercialize-novel-formulations-and-combinations-of-medicines-in-emerging-markets\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck &#038; Co., Inc., and Sun Pharma Establish Joint Venture to Develop and Commercialize Novel Formulations and Combinations of Medicines in Emerging Markets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck &amp; Co., Inc., and Sun Pharma Establish Joint Venture to Develop and Commercialize Novel Formulations and Combinations of Medicines in Emerging Markets - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-co-inc-and-sun-pharma-establish-joint-venture-to-develop-and-commercialize-novel-formulations-and-combinations-of-medicines-in-emerging-markets\/","og_locale":"en_US","og_type":"article","og_title":"Merck &amp; Co., Inc., and Sun Pharma Establish Joint Venture to Develop and Commercialize Novel Formulations and Combinations of Medicines in Emerging Markets - Merck.com","og_description":"Joint Venture to Apply Proprietary Technologies to Develop Medicines Designed to Enhance Convenience and Improve Compliance Merck &amp; Co., Inc., (NYSE:MRK), a global health care leader, known as MSD outside the United States and Canada, and Sun Pharmaceutical Industries Ltd., (\u201cSun Pharma\u201d) a leading Indian multinational pharmaceutical company, today announced the creation of a joint venture to develop, manufacture and commercialize new combinations and formulations of innovative, branded generics in the Emerging Markets. \"Merck's Emerging Markets strategy is driven by our overarching focus on applying innovation across our business from introducing novel compounds to broadening our focus on innovative branded generics,\" said Kevin Ali, president, Emerging Markets, Merck\/MSD. \"By combining forces with Sun Pharma, we are complementing our innovative product portfolio with a solid foundation for addressing the diverse needs of patients, physicians and governments across the Emerging","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-co-inc-and-sun-pharma-establish-joint-venture-to-develop-and-commercialize-novel-formulations-and-combinations-of-medicines-in-emerging-markets\/","og_site_name":"Merck.com","article_modified_time":"2026-08-10T17:01:18+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120521005627r1&amp;sid=sfsite1&amp;distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-co-inc-and-sun-pharma-establish-joint-venture-to-develop-and-commercialize-novel-formulations-and-combinations-of-medicines-in-emerging-markets\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-co-inc-and-sun-pharma-establish-joint-venture-to-develop-and-commercialize-novel-formulations-and-combinations-of-medicines-in-emerging-markets\/","name":"Merck &amp; Co., Inc., and Sun Pharma Establish Joint Venture to Develop and Commercialize Novel Formulations and Combinations of Medicines in Emerging Markets - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-co-inc-and-sun-pharma-establish-joint-venture-to-develop-and-commercialize-novel-formulations-and-combinations-of-medicines-in-emerging-markets\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-co-inc-and-sun-pharma-establish-joint-venture-to-develop-and-commercialize-novel-formulations-and-combinations-of-medicines-in-emerging-markets\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120521005627r1&amp;sid=sfsite1&amp;distro=nx","datePublished":"2011-04-11T07:01:00+00:00","dateModified":"2026-08-10T17:01:18+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-co-inc-and-sun-pharma-establish-joint-venture-to-develop-and-commercialize-novel-formulations-and-combinations-of-medicines-in-emerging-markets\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-co-inc-and-sun-pharma-establish-joint-venture-to-develop-and-commercialize-novel-formulations-and-combinations-of-medicines-in-emerging-markets\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-co-inc-and-sun-pharma-establish-joint-venture-to-develop-and-commercialize-novel-formulations-and-combinations-of-medicines-in-emerging-markets\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120521005627r1&amp;sid=sfsite1&amp;distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120521005627r1&amp;sid=sfsite1&amp;distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-co-inc-and-sun-pharma-establish-joint-venture-to-develop-and-commercialize-novel-formulations-and-combinations-of-medicines-in-emerging-markets\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck &#038; Co., Inc., and Sun Pharma Establish Joint Venture to Develop and Commercialize Novel Formulations and Combinations of Medicines in Emerging Markets"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"440e983a-f971-4167-9729-54ba556ac97d","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck--Co-Inc-and-Sun-Pharma-Establish-Joint-Venture-to-Develop-and-Commercialize-Novel-Formulations-and-Combinations-of-Medicines-in-LPX2A.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742130","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742130\/revisions"}],"predecessor-version":[{"id":3679266,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742130\/revisions\/3679266"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742130"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742130"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}